Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck

Clint T Allen, Justin L. Ricker, Zhong Chen, Carter Van Waes

Research output: Contribution to journalArticle

Abstract

Background. Nuclear factor-κB (NF-κB), a transcription factor known to modulate expression of factors involved in inflammation, immunity, proliferation, and apoptosis, is constitutively activated and plays a role in pathogenesis and therapeutic resistance in head and neck squamous cell carcinoma (HNSCC). Understanding the molecular alterations leading to aberrant NF-κB activation in HNSCC may direct investigators to novel therapeutic targets. Methods. Results of laboratory and clinical studies are reviewed. Results. The structure, function, and activation of NF-κB, products of NF-κB target genes and their role in HNSCC oncogenesis, and current NF-κB modulating interventions are described. Conclusions. Aberrant NF-κB activation contributes to the expression of oncogenes and the malignant phenotype observed in HNSCC. NF-κB, along with providing a link between cancer and inflammation, may serve as an appropriate therapeutic target to inhibit tumor growth and sensitize cancer cells to established cytotoxic anticancer therapies.

Original languageEnglish (US)
Pages (from-to)959-971
Number of pages13
JournalHead and Neck
Volume29
Issue number10
DOIs
StatePublished - Oct 2007

Fingerprint

Inflammation
Neoplasms
Therapeutics
Oncogenes
Immunity
Carcinogenesis
Transcription Factors
Research Personnel
Apoptosis
Phenotype
Carcinoma, squamous cell of head and neck
Growth
Genes
Clinical Studies

Keywords

  • Bortezomib
  • EGFR
  • Head and neck squamous cell carcinoma
  • Nuclear factor-κB
  • Signal transduction

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. / Allen, Clint T; Ricker, Justin L.; Chen, Zhong; Van Waes, Carter.

In: Head and Neck, Vol. 29, No. 10, 10.2007, p. 959-971.

Research output: Contribution to journalArticle

Allen, Clint T ; Ricker, Justin L. ; Chen, Zhong ; Van Waes, Carter. / Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. In: Head and Neck. 2007 ; Vol. 29, No. 10. pp. 959-971.
@article{de3895caae094baf92cf7b5b07b9eb81,
title = "Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck",
abstract = "Background. Nuclear factor-κB (NF-κB), a transcription factor known to modulate expression of factors involved in inflammation, immunity, proliferation, and apoptosis, is constitutively activated and plays a role in pathogenesis and therapeutic resistance in head and neck squamous cell carcinoma (HNSCC). Understanding the molecular alterations leading to aberrant NF-κB activation in HNSCC may direct investigators to novel therapeutic targets. Methods. Results of laboratory and clinical studies are reviewed. Results. The structure, function, and activation of NF-κB, products of NF-κB target genes and their role in HNSCC oncogenesis, and current NF-κB modulating interventions are described. Conclusions. Aberrant NF-κB activation contributes to the expression of oncogenes and the malignant phenotype observed in HNSCC. NF-κB, along with providing a link between cancer and inflammation, may serve as an appropriate therapeutic target to inhibit tumor growth and sensitize cancer cells to established cytotoxic anticancer therapies.",
keywords = "Bortezomib, EGFR, Head and neck squamous cell carcinoma, Nuclear factor-κB, Signal transduction",
author = "Allen, {Clint T} and Ricker, {Justin L.} and Zhong Chen and {Van Waes}, Carter",
year = "2007",
month = "10",
doi = "10.1002/hed.20615",
language = "English (US)",
volume = "29",
pages = "959--971",
journal = "Head and Neck Surgery",
issn = "0148-6403",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Role of activated nuclear factor-κB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck

AU - Allen, Clint T

AU - Ricker, Justin L.

AU - Chen, Zhong

AU - Van Waes, Carter

PY - 2007/10

Y1 - 2007/10

N2 - Background. Nuclear factor-κB (NF-κB), a transcription factor known to modulate expression of factors involved in inflammation, immunity, proliferation, and apoptosis, is constitutively activated and plays a role in pathogenesis and therapeutic resistance in head and neck squamous cell carcinoma (HNSCC). Understanding the molecular alterations leading to aberrant NF-κB activation in HNSCC may direct investigators to novel therapeutic targets. Methods. Results of laboratory and clinical studies are reviewed. Results. The structure, function, and activation of NF-κB, products of NF-κB target genes and their role in HNSCC oncogenesis, and current NF-κB modulating interventions are described. Conclusions. Aberrant NF-κB activation contributes to the expression of oncogenes and the malignant phenotype observed in HNSCC. NF-κB, along with providing a link between cancer and inflammation, may serve as an appropriate therapeutic target to inhibit tumor growth and sensitize cancer cells to established cytotoxic anticancer therapies.

AB - Background. Nuclear factor-κB (NF-κB), a transcription factor known to modulate expression of factors involved in inflammation, immunity, proliferation, and apoptosis, is constitutively activated and plays a role in pathogenesis and therapeutic resistance in head and neck squamous cell carcinoma (HNSCC). Understanding the molecular alterations leading to aberrant NF-κB activation in HNSCC may direct investigators to novel therapeutic targets. Methods. Results of laboratory and clinical studies are reviewed. Results. The structure, function, and activation of NF-κB, products of NF-κB target genes and their role in HNSCC oncogenesis, and current NF-κB modulating interventions are described. Conclusions. Aberrant NF-κB activation contributes to the expression of oncogenes and the malignant phenotype observed in HNSCC. NF-κB, along with providing a link between cancer and inflammation, may serve as an appropriate therapeutic target to inhibit tumor growth and sensitize cancer cells to established cytotoxic anticancer therapies.

KW - Bortezomib

KW - EGFR

KW - Head and neck squamous cell carcinoma

KW - Nuclear factor-κB

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=38449103501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449103501&partnerID=8YFLogxK

U2 - 10.1002/hed.20615

DO - 10.1002/hed.20615

M3 - Article

C2 - 17405170

AN - SCOPUS:38449103501

VL - 29

SP - 959

EP - 971

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 0148-6403

IS - 10

ER -